Maroun J
Ontario Cancer Foundation, Ottawa Clinic, Ontario.
Semin Oncol. 1988 Apr;15(2 Suppl 2):17-21.
Trimetrexate glucuronate was evaluated in 70 nonsmall cell lung cancer patients with incurable disease and/or demonstrated progression following surgery/radiotherapy and no prior cytotoxic chemotherapy. Trimetrexate was initially administered at 8 mg/m2 intravenously (IV) daily for 5 days and repeated every 3 to 4 weeks with dose adjustments depending on patient tolerance. A median of two courses of trimetrexate therapy was administered (range 1 to 12). Fifty-nine (84%) patients were evaluable for response. Eleven patients (19%) achieved a partial response with a median duration of 15.3 weeks. The median time to response was 4.6 weeks. Twenty-three patients (39%) had stable disease with a median time to progression of 15.7 weeks. The median survival for evaluable patients was 26.4 weeks. Trimetrexate was well tolerated with manageable myelosuppression as the dose limiting toxicity. Trimetrexate was shown to have activity in nonsmall cell lung cancer.
对70例患有无法治愈疾病和/或在手术/放疗后病情进展且此前未接受过细胞毒性化疗的非小细胞肺癌患者进行了葡糖醛酸三甲曲沙评估。三甲曲沙最初以8 mg/m²的剂量静脉注射，每日1次，共5天，每3至4周重复一次，并根据患者耐受性调整剂量。三甲曲沙治疗的疗程中位数为2个（范围1至12个）。59例（84%）患者可评估疗效。11例患者（19%）获得部分缓解，中位缓解持续时间为15.3周。中位起效时间为4.6周。23例患者（39%）病情稳定，中位疾病进展时间为15.7周。可评估患者的中位生存期为26.4周。三甲曲沙耐受性良好，剂量限制性毒性为可控的骨髓抑制。结果表明，三甲曲沙对非小细胞肺癌有活性。
